Ascendis Pharma issues 210,812 shares via warrants

The issuance brought Ascendis Pharma A/S’s aggregate share capital to nominal DKK 66,400,738, with average cash consideration of approximately USD $123.36 per share.

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) said its outstanding-warrant exercise window closed on September 29, 2026. During the window, the company registered aggregate share capital increases of nominal DKK 210,812 through the issuance of 210,812 ordinary shares against average cash consideration of approximately USD $123.36 per share, based on the DKK-USD exchange rate on September 29, 2026. Its aggregate share capital increased to nominal DKK 66,400,738, and its articles of association were amended accordingly.

Filing Explained

The 210,812 shares issued through warrant exercises increase Ascendis’s share count and, absent offsetting changes, reduce existing holders’ percentage ownership; the exercise window is closed.

Key Figures

Registered share capital increase: DKK 210,812 nominal Ordinary shares issued: 210,812 shares Average cash consideration: Approximately USD $123.36 per share +1 more

4 metrics

Registered share capital increase DKK 210,812 nominal Registered in connection with warrant exercises during the window closed September 29, 2026

Ordinary shares issued 210,812 shares Issued in connection with exercises of certain warrants

Average cash consideration Approximately USD $123.36 per share Based on the DKK-USD exchange rate on September 29, 2026

Aggregate share capital DKK 66,400,738 nominal After the registered share capital increase

Key Terms

exercise window, nominal value, share capital increases

3 terms

exercise window financial

"an exercise window closed for the Company’s outstanding warrants"

nominal value financial

"ordinary shares, nominal value DKK 1"

Nominal value is the stated or face amount assigned to a financial instrument — for shares it’s the par value printed on the stock certificate, and for money or returns it can mean the number not adjusted for inflation. Think of it like a price tag on an item versus its buying power: the tag tells you the label, but not how much you can actually buy. Investors care because nominal values affect accounting, legal capital, dividend calculations and comparisons over time when inflation may distort real worth.

share capital increases financial

"registered aggregate share capital increases of nominal DKK 210,812"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did ASND issue in the warrant exercise window?

Ascendis Pharma A/S issued 210,812 ordinary shares during the exercise window, which closed September 29, 2026.

What was the average cash consideration per ASND share issued?

The average cash consideration was approximately USD $123.36 per share, based on the DKK-USD exchange rate on September 29, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 04:03 PM Accepted by SEC EDGAR 09/29/2026 - 04:02 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2026

Commission File Number: 001-36815

Ascendis Pharma A/S

(Translation of registrant’s name into English)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-228576, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, 333-285322 and 333-293854) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the “Company” or “Ascendis”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Closing of Warrant Exercise Window

On September 29, 2026, an exercise window closed for the Company’s outstanding warrants exercisable for the Company’s ordinary shares, nominal value DKK 1. In connection with the exercises of certain of such warrants during this exercise window, the Company registered aggregate share capital increases of nominal DKK 210,812 with the Danish Business Authority, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 66,400,738 through the issuance of 210,812 ordinary shares against average cash consideration of approximately USD $123.36 per share, based on the DKK-USD exchange rate on September 29, 2026. The Company’s articles of association were amended accordingly and are attached hereto as Exhibit 1.1.

Exhibits

Exhibit No.		Description
1.1		Articles of Association.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: September 29, 2026				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-1.1 EX-1.1 504.6 KB